PET Biomarkers in Lymphoma
![PET Biomarkers in Lymphoma image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FJuan%252520A_41840c2c-a2d7-4fdd-99ef-6461a85a6fe2.jpg%253Falt%253Dmedia)
PET Biomarkers in Lymphoma
Event Description
This event will not be live-streamed; it will be recorded on February 26th. You can submit your questions in advance by clicking "notify when available" above and enter your question in the box. We will ask the submitted questions during the Q&A at the end.
Defining and tracking progression/remission in DLBCL patients can be subjective and complicated. In this episode, we are joined by Dr. Juan Pablo Alderuccio. Dr. Alderuccio recently published his research on PET-based biomarkers in lymphoma patients. His research aims to give patients a more accurate knowledge of their lymphoma prognosis.
Thank you to our episode sponsor, Regeneron.
Schedule & Agenda
Speakers & Moderators
![The panelist Kat Richardson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FKat_205dcbf3-d19c-4c3b-88b0-8f8b1d620abe.jpeg?alt=media)
Kat is from Lehi, Utah and is the Health Education Manager for lymphoma. She has worked in healthcare for a decade now, and earned her degree in Community Health Education and Promotion. Kat is passionate about disease prevention as well as improving quality of life and health equity. She enjoys reading, hiking, baking, ice skating, gardening, time with her family and friends, and most of all, spoiling her nieces and nephew.
![The panelist Dr. Juan Pablo Alderuccio](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJuan%20A_41840c2c-a2d7-4fdd-99ef-6461a85a6fe2.jpg?alt=media)
Dr. Alderuccio is a clinical investigator who specializes in the study and treatment of patients with lymphoma. His area of primary research is clinical and translational research in lymphoma. He has a strong interest in indolent and aggressive lymphomas, particularly in the implementation of quantitative FDG-PET/CT analysis in the risk stratification and evaluation of novel therapies in lymphoma patients.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Follicular lymphoma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Follicular Lymphoma Sponsors:
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_logo_(2).svg_64899492-87cd-4df9-9d4b-07f9618df890.png?alt=media)
![Bristol Myers Squibb](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FBristol%20Myers%20Squibb_f22fa9b6-b205-4828-bea5-d645566d3243.png?alt=media)